ArticleTherapeutic advances in medical oncology2026

Gastrointestinal adverse events following brentuximab vedotin and polatuzumab vedotin therapy.

Andrew G Kuang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.